TW
ABBV icon

Traveka Wealth’s AbbVie ABBV Stock Holding History

Traveka Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$939K Buy
3,731
+83
+2% +$17.9K 0.31% 65
2026
Q1 		$793K Buy
3,648
+27
+0.7% +$5.99K 0.3% 64
2025
Q4 		$827K Sell
3,621
-449
-11% -$102K 0.34% 58
2025
Q3 		$942K Buy
4,070
+76
+2% +$15.5K 0.42% 45
2025
Q2 		$741K Buy
3,994
+66
+2% +$12.3K 0.39% 48
2025
Q1 		$823K Buy
3,928
+23
+0.6% +$4.47K 0.46% 45
2024
Q4 		$694K Buy
3,905
+1,668
+75% +$307K 0.38% 52
2024
Q3 		$442K Buy
2,237
+83
+4% +$15.5K 0.22% 64
2024
Q2 		$369K Buy
2,154
+70
+3% +$11.6K 0.18% 70
2024
Q1 		$379K Sell
2,084
-1,875
-47% -$323K 0.18% 66
2023
Q4 		$614K Buy
+3,959
New +$577K 0.31% 51

Other funds holding ABBV

Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.94% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Traveka Wealth's ABBV Position: Q2 2026 in Review

Traveka Wealth increased its AbbVie (ABBV) stake by 2.3% in Q2 2026, buying an estimated $17.9K and bringing the position to 3,731 shares worth $939K. The position accounts for 0.31% of the portfolio, ranked #65.

Traveka Wealth first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. The position peaked at $942K in Q3 2025. 2,241 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Traveka Wealth held 3,731 shares of AbbVie worth $939K as of Q2 2026.
  • Traveka Wealth bought 83 AbbVie shares in Q2 2026, an estimated $17.9K.
  • AbbVie made up 0.31% of Traveka Wealth's portfolio in Q2 2026, its #65 holding.
  • Traveka Wealth first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • Traveka Wealth's AbbVie position peaked at $942K in Q3 2025.
  • 2,241 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Traveka Wealth's 13F filing for Q2 2026, filed 21 Jul 2026.